Stephane Ferretti

Basel, BS 4056, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapy.

Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapy.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 22, 2026

Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates.

Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates.

Journal: Bioconjugate chemistry

Published: January 24, 2024

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.

Journal: Nature

Published: July 26, 2023

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 08, 2021

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 08, 2021

CARD10 cleavage by MALT1 restricts lung carcinoma growth in vivo.

CARD10 cleavage by MALT1 restricts lung carcinoma growth in vivo.

Journal: Oncogenesis

Published: December 11, 2020

Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.

Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.

Journal: British journal of cancer

Published: November 23, 2020

Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms.

Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms.

Journal: ACS pharmacology & translational science

Published: November 15, 2020

Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201.

Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201.

Journal: The AAPS journal

Published: September 03, 2020

PAX8 and MECOM are interaction partners driving ovarian cancer.

PAX8 and MECOM are interaction partners driving ovarian cancer.

Journal: Nature communications

Published: July 27, 2020

p53 dynamics vary between tissues and are linked with radiation sensitivity.

p53 dynamics vary between tissues and are linked with radiation sensitivity.

Journal: Nature communications

Published: September 16, 2019

Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models.

Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models.

Journal: Computational and structural biotechnology journal

Published: August 07, 2019

Showing 1-12 of 26

Last Updated: 09/26/2026